nodes	percent_of_prediction	percent_of_DWPC	metapath
Treprostinil—CYP2C9—Anastrozole—breast cancer	0.0989	0.332	CbGbCtD
Treprostinil—CYP2C9—Idarubicin—breast cancer	0.075	0.251	CbGbCtD
Treprostinil—CYP2C9—Capecitabine—breast cancer	0.0411	0.138	CbGbCtD
Treprostinil—CYP2C9—Tamoxifen—breast cancer	0.0331	0.111	CbGbCtD
Treprostinil—CYP2C9—Paclitaxel—breast cancer	0.0257	0.0863	CbGbCtD
Treprostinil—CYP2C9—Fluorouracil—breast cancer	0.0244	0.0817	CbGbCtD
Treprostinil—PPARD—mammary gland—breast cancer	0.00795	0.144	CbGeAlD
Treprostinil—Epoprostenol—PTGER1—breast cancer	0.00723	0.93	CrCbGaD
Treprostinil—P2RY12—epithelium—breast cancer	0.00533	0.0964	CbGeAlD
Treprostinil—PPARD—adipose tissue—breast cancer	0.00358	0.0647	CbGeAlD
Treprostinil—PTGIR—epithelium—breast cancer	0.0034	0.0615	CbGeAlD
Treprostinil—P2RY12—endocrine gland—breast cancer	0.00335	0.0606	CbGeAlD
Treprostinil—PPARD—female reproductive system—breast cancer	0.00329	0.0595	CbGeAlD
Treprostinil—PPARD—adrenal gland—breast cancer	0.00321	0.058	CbGeAlD
Treprostinil—PPARD—female gonad—breast cancer	0.00299	0.0541	CbGeAlD
Treprostinil—PPARD—endocrine gland—breast cancer	0.00278	0.0503	CbGeAlD
Treprostinil—PTGIR—adipose tissue—breast cancer	0.00275	0.0497	CbGeAlD
Treprostinil—PTGIR—female reproductive system—breast cancer	0.00253	0.0457	CbGeAlD
Treprostinil—PTGIR—adrenal gland—breast cancer	0.00247	0.0446	CbGeAlD
Treprostinil—PTGIR—female gonad—breast cancer	0.0023	0.0416	CbGeAlD
Treprostinil—CYP2C9—mammary gland—breast cancer	0.00218	0.0394	CbGeAlD
Treprostinil—PTGIR—endocrine gland—breast cancer	0.00214	0.0386	CbGeAlD
Treprostinil—PPARD—lymph node—breast cancer	0.00192	0.0348	CbGeAlD
Treprostinil—PTGIR—lymph node—breast cancer	0.00148	0.0267	CbGeAlD
Treprostinil—CYP2C9—female reproductive system—breast cancer	0.000903	0.0163	CbGeAlD
Treprostinil—CYP2C9—endocrine gland—breast cancer	0.000764	0.0138	CbGeAlD
Treprostinil—Nadolol—ABCB1—breast cancer	0.000541	0.0696	CrCbGaD
Treprostinil—Chest pain—Capecitabine—breast cancer	0.000132	0.00035	CcSEcCtD
Treprostinil—Pain—Paclitaxel—breast cancer	0.000132	0.00035	CcSEcCtD
Treprostinil—Haematuria—Epirubicin—breast cancer	0.000132	0.00035	CcSEcCtD
Treprostinil—Pharyngitis—Methotrexate—breast cancer	0.000132	0.000349	CcSEcCtD
Treprostinil—Anxiety—Capecitabine—breast cancer	0.000132	0.000349	CcSEcCtD
Treprostinil—Oedema—Docetaxel—breast cancer	0.000131	0.000347	CcSEcCtD
Treprostinil—Discomfort—Capecitabine—breast cancer	0.00013	0.000346	CcSEcCtD
Treprostinil—Epistaxis—Epirubicin—breast cancer	0.00013	0.000346	CcSEcCtD
Treprostinil—Pruritus—Gemcitabine—breast cancer	0.00013	0.000346	CcSEcCtD
Treprostinil—Nausea—Thiotepa—breast cancer	0.00013	0.000345	CcSEcCtD
Treprostinil—Infection—Docetaxel—breast cancer	0.00013	0.000345	CcSEcCtD
Treprostinil—Sinusitis—Epirubicin—breast cancer	0.00013	0.000344	CcSEcCtD
Treprostinil—Diarrhoea—Irinotecan—breast cancer	0.000129	0.000343	CcSEcCtD
Treprostinil—Diarrhoea—Mitoxantrone—breast cancer	0.000129	0.000343	CcSEcCtD
Treprostinil—Pneumonia—Doxorubicin—breast cancer	0.000129	0.000341	CcSEcCtD
Treprostinil—Shock—Docetaxel—breast cancer	0.000129	0.000341	CcSEcCtD
Treprostinil—Pruritus—Fluorouracil—breast cancer	0.000128	0.00034	CcSEcCtD
Treprostinil—Thrombocytopenia—Docetaxel—breast cancer	0.000128	0.00034	CcSEcCtD
Treprostinil—Tachycardia—Docetaxel—breast cancer	0.000128	0.000339	CcSEcCtD
Treprostinil—Feeling abnormal—Paclitaxel—breast cancer	0.000127	0.000337	CcSEcCtD
Treprostinil—Oedema—Capecitabine—breast cancer	0.000127	0.000336	CcSEcCtD
Treprostinil—Bradycardia—Epirubicin—breast cancer	0.000126	0.000335	CcSEcCtD
Treprostinil—Gastrointestinal pain—Paclitaxel—breast cancer	0.000126	0.000335	CcSEcCtD
Treprostinil—Diarrhoea—Gemcitabine—breast cancer	0.000126	0.000335	CcSEcCtD
Treprostinil—Infection—Capecitabine—breast cancer	0.000126	0.000334	CcSEcCtD
Treprostinil—Dizziness—Irinotecan—breast cancer	0.000125	0.000332	CcSEcCtD
Treprostinil—Haemoglobin—Epirubicin—breast cancer	0.000125	0.000331	CcSEcCtD
Treprostinil—Anorexia—Docetaxel—breast cancer	0.000125	0.000331	CcSEcCtD
Treprostinil—Shock—Capecitabine—breast cancer	0.000125	0.000331	CcSEcCtD
Treprostinil—Rhinitis—Epirubicin—breast cancer	0.000124	0.00033	CcSEcCtD
Treprostinil—Urinary tract infection—Doxorubicin—breast cancer	0.000124	0.00033	CcSEcCtD
Treprostinil—Haemorrhage—Epirubicin—breast cancer	0.000124	0.000329	CcSEcCtD
Treprostinil—Diarrhoea—Fluorouracil—breast cancer	0.000124	0.000329	CcSEcCtD
Treprostinil—Thrombocytopenia—Capecitabine—breast cancer	0.000124	0.000329	CcSEcCtD
Treprostinil—Tachycardia—Capecitabine—breast cancer	0.000124	0.000328	CcSEcCtD
Treprostinil—Pharyngitis—Epirubicin—breast cancer	0.000123	0.000327	CcSEcCtD
Treprostinil—Oedema peripheral—Epirubicin—breast cancer	0.000122	0.000325	CcSEcCtD
Treprostinil—Hypotension—Docetaxel—breast cancer	0.000122	0.000324	CcSEcCtD
Treprostinil—Haematuria—Doxorubicin—breast cancer	0.000122	0.000324	CcSEcCtD
Treprostinil—Abdominal pain—Paclitaxel—breast cancer	0.000122	0.000324	CcSEcCtD
Treprostinil—Body temperature increased—Paclitaxel—breast cancer	0.000122	0.000324	CcSEcCtD
Treprostinil—Epistaxis—Doxorubicin—breast cancer	0.000121	0.00032	CcSEcCtD
Treprostinil—Anorexia—Capecitabine—breast cancer	0.000121	0.00032	CcSEcCtD
Treprostinil—Vomiting—Irinotecan—breast cancer	0.00012	0.000319	CcSEcCtD
Treprostinil—Vomiting—Mitoxantrone—breast cancer	0.00012	0.000319	CcSEcCtD
Treprostinil—Sinusitis—Doxorubicin—breast cancer	0.00012	0.000319	CcSEcCtD
Treprostinil—Dizziness—Fluorouracil—breast cancer	0.00012	0.000318	CcSEcCtD
Treprostinil—Rash—Mitoxantrone—breast cancer	0.000119	0.000316	CcSEcCtD
Treprostinil—Rash—Irinotecan—breast cancer	0.000119	0.000316	CcSEcCtD
Treprostinil—Dermatitis—Mitoxantrone—breast cancer	0.000119	0.000316	CcSEcCtD
Treprostinil—Dermatitis—Irinotecan—breast cancer	0.000119	0.000316	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Docetaxel—breast cancer	0.000119	0.000316	CcSEcCtD
Treprostinil—Headache—Mitoxantrone—breast cancer	0.000119	0.000314	CcSEcCtD
Treprostinil—Headache—Irinotecan—breast cancer	0.000119	0.000314	CcSEcCtD
Treprostinil—Hypotension—Capecitabine—breast cancer	0.000118	0.000314	CcSEcCtD
Treprostinil—Insomnia—Docetaxel—breast cancer	0.000118	0.000314	CcSEcCtD
Treprostinil—Paraesthesia—Docetaxel—breast cancer	0.000117	0.000312	CcSEcCtD
Treprostinil—Vomiting—Gemcitabine—breast cancer	0.000117	0.000311	CcSEcCtD
Treprostinil—Bradycardia—Doxorubicin—breast cancer	0.000117	0.00031	CcSEcCtD
Treprostinil—Dyspnoea—Docetaxel—breast cancer	0.000117	0.000309	CcSEcCtD
Treprostinil—Rash—Gemcitabine—breast cancer	0.000116	0.000308	CcSEcCtD
Treprostinil—Dermatitis—Gemcitabine—breast cancer	0.000116	0.000308	CcSEcCtD
Treprostinil—Erythema—Methotrexate—breast cancer	0.000115	0.000306	CcSEcCtD
Treprostinil—Haemoglobin—Doxorubicin—breast cancer	0.000115	0.000306	CcSEcCtD
Treprostinil—Headache—Gemcitabine—breast cancer	0.000115	0.000306	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000115	0.000306	CcSEcCtD
Treprostinil—Flushing—Epirubicin—breast cancer	0.000115	0.000306	CcSEcCtD
Treprostinil—Vomiting—Fluorouracil—breast cancer	0.000115	0.000306	CcSEcCtD
Treprostinil—Rhinitis—Doxorubicin—breast cancer	0.000115	0.000306	CcSEcCtD
Treprostinil—Dyspepsia—Docetaxel—breast cancer	0.000115	0.000305	CcSEcCtD
Treprostinil—Haemorrhage—Doxorubicin—breast cancer	0.000115	0.000305	CcSEcCtD
Treprostinil—Insomnia—Capecitabine—breast cancer	0.000115	0.000304	CcSEcCtD
Treprostinil—Rash—Fluorouracil—breast cancer	0.000114	0.000303	CcSEcCtD
Treprostinil—Dermatitis—Fluorouracil—breast cancer	0.000114	0.000303	CcSEcCtD
Treprostinil—Pharyngitis—Doxorubicin—breast cancer	0.000114	0.000303	CcSEcCtD
Treprostinil—Paraesthesia—Capecitabine—breast cancer	0.000114	0.000302	CcSEcCtD
Treprostinil—Decreased appetite—Docetaxel—breast cancer	0.000114	0.000302	CcSEcCtD
Treprostinil—Headache—Fluorouracil—breast cancer	0.000114	0.000301	CcSEcCtD
Treprostinil—Oedema peripheral—Doxorubicin—breast cancer	0.000113	0.0003	CcSEcCtD
Treprostinil—Dyspnoea—Capecitabine—breast cancer	0.000113	0.000299	CcSEcCtD
Treprostinil—Fatigue—Docetaxel—breast cancer	0.000113	0.000299	CcSEcCtD
Treprostinil—Nausea—Mitoxantrone—breast cancer	0.000112	0.000298	CcSEcCtD
Treprostinil—Nausea—Irinotecan—breast cancer	0.000112	0.000298	CcSEcCtD
Treprostinil—Pain—Docetaxel—breast cancer	0.000112	0.000297	CcSEcCtD
Treprostinil—Back pain—Methotrexate—breast cancer	0.000112	0.000296	CcSEcCtD
Treprostinil—Dyspepsia—Capecitabine—breast cancer	0.000111	0.000296	CcSEcCtD
Treprostinil—Asthenia—Paclitaxel—breast cancer	0.000111	0.000294	CcSEcCtD
Treprostinil—Decreased appetite—Capecitabine—breast cancer	0.00011	0.000292	CcSEcCtD
Treprostinil—Nausea—Gemcitabine—breast cancer	0.000109	0.00029	CcSEcCtD
Treprostinil—Fatigue—Capecitabine—breast cancer	0.000109	0.00029	CcSEcCtD
Treprostinil—Pruritus—Paclitaxel—breast cancer	0.000109	0.00029	CcSEcCtD
Treprostinil—Pain—Capecitabine—breast cancer	0.000108	0.000287	CcSEcCtD
Treprostinil—Erythema—Epirubicin—breast cancer	0.000108	0.000287	CcSEcCtD
Treprostinil—Feeling abnormal—Docetaxel—breast cancer	0.000108	0.000286	CcSEcCtD
Treprostinil—Nausea—Fluorouracil—breast cancer	0.000108	0.000286	CcSEcCtD
Treprostinil—Ill-defined disorder—Methotrexate—breast cancer	0.000107	0.000284	CcSEcCtD
Treprostinil—Gastrointestinal pain—Docetaxel—breast cancer	0.000107	0.000284	CcSEcCtD
Treprostinil—Anaemia—Methotrexate—breast cancer	0.000107	0.000283	CcSEcCtD
Treprostinil—Flushing—Doxorubicin—breast cancer	0.000107	0.000283	CcSEcCtD
Treprostinil—Tension—Epirubicin—breast cancer	0.000106	0.000281	CcSEcCtD
Treprostinil—Diarrhoea—Paclitaxel—breast cancer	0.000106	0.00028	CcSEcCtD
Treprostinil—Nervousness—Epirubicin—breast cancer	0.000105	0.000279	CcSEcCtD
Treprostinil—Back pain—Epirubicin—breast cancer	0.000105	0.000277	CcSEcCtD
Treprostinil—Feeling abnormal—Capecitabine—breast cancer	0.000104	0.000277	CcSEcCtD
Treprostinil—Malaise—Methotrexate—breast cancer	0.000104	0.000276	CcSEcCtD
Treprostinil—Muscle spasms—Epirubicin—breast cancer	0.000104	0.000276	CcSEcCtD
Treprostinil—Gastrointestinal pain—Capecitabine—breast cancer	0.000104	0.000275	CcSEcCtD
Treprostinil—Body temperature increased—Docetaxel—breast cancer	0.000103	0.000274	CcSEcCtD
Treprostinil—Abdominal pain—Docetaxel—breast cancer	0.000103	0.000274	CcSEcCtD
Treprostinil—Dizziness—Paclitaxel—breast cancer	0.000102	0.000271	CcSEcCtD
Treprostinil—Cough—Methotrexate—breast cancer	0.000101	0.000267	CcSEcCtD
Treprostinil—Ill-defined disorder—Epirubicin—breast cancer	0.0001	0.000266	CcSEcCtD
Treprostinil—Body temperature increased—Capecitabine—breast cancer	0.0001	0.000266	CcSEcCtD
Treprostinil—Abdominal pain—Capecitabine—breast cancer	0.0001	0.000266	CcSEcCtD
Treprostinil—Erythema—Doxorubicin—breast cancer	0.0001	0.000265	CcSEcCtD
Treprostinil—Anaemia—Epirubicin—breast cancer	9.99e-05	0.000265	CcSEcCtD
Treprostinil—Arthralgia—Methotrexate—breast cancer	9.83e-05	0.000261	CcSEcCtD
Treprostinil—Myalgia—Methotrexate—breast cancer	9.83e-05	0.000261	CcSEcCtD
Treprostinil—Chest pain—Methotrexate—breast cancer	9.83e-05	0.000261	CcSEcCtD
Treprostinil—Tension—Doxorubicin—breast cancer	9.81e-05	0.00026	CcSEcCtD
Treprostinil—Vomiting—Paclitaxel—breast cancer	9.81e-05	0.00026	CcSEcCtD
Treprostinil—Malaise—Epirubicin—breast cancer	9.75e-05	0.000259	CcSEcCtD
Treprostinil—Rash—Paclitaxel—breast cancer	9.73e-05	0.000258	CcSEcCtD
Treprostinil—Dermatitis—Paclitaxel—breast cancer	9.72e-05	0.000258	CcSEcCtD
Treprostinil—Discomfort—Methotrexate—breast cancer	9.71e-05	0.000258	CcSEcCtD
Treprostinil—Nervousness—Doxorubicin—breast cancer	9.71e-05	0.000258	CcSEcCtD
Treprostinil—Syncope—Epirubicin—breast cancer	9.69e-05	0.000257	CcSEcCtD
Treprostinil—Back pain—Doxorubicin—breast cancer	9.67e-05	0.000257	CcSEcCtD
Treprostinil—Headache—Paclitaxel—breast cancer	9.67e-05	0.000256	CcSEcCtD
Treprostinil—Muscle spasms—Doxorubicin—breast cancer	9.61e-05	0.000255	CcSEcCtD
Treprostinil—Palpitations—Epirubicin—breast cancer	9.55e-05	0.000253	CcSEcCtD
Treprostinil—Loss of consciousness—Epirubicin—breast cancer	9.5e-05	0.000252	CcSEcCtD
Treprostinil—Cough—Epirubicin—breast cancer	9.43e-05	0.00025	CcSEcCtD
Treprostinil—Asthenia—Docetaxel—breast cancer	9.38e-05	0.000249	CcSEcCtD
Treprostinil—Infection—Methotrexate—breast cancer	9.36e-05	0.000248	CcSEcCtD
Treprostinil—Ill-defined disorder—Doxorubicin—breast cancer	9.28e-05	0.000246	CcSEcCtD
Treprostinil—Pruritus—Docetaxel—breast cancer	9.25e-05	0.000245	CcSEcCtD
Treprostinil—Anaemia—Doxorubicin—breast cancer	9.24e-05	0.000245	CcSEcCtD
Treprostinil—Thrombocytopenia—Methotrexate—breast cancer	9.23e-05	0.000245	CcSEcCtD
Treprostinil—Arthralgia—Epirubicin—breast cancer	9.2e-05	0.000244	CcSEcCtD
Treprostinil—Chest pain—Epirubicin—breast cancer	9.2e-05	0.000244	CcSEcCtD
Treprostinil—Myalgia—Epirubicin—breast cancer	9.2e-05	0.000244	CcSEcCtD
Treprostinil—Anxiety—Epirubicin—breast cancer	9.17e-05	0.000243	CcSEcCtD
Treprostinil—Nausea—Paclitaxel—breast cancer	9.16e-05	0.000243	CcSEcCtD
Treprostinil—Discomfort—Epirubicin—breast cancer	9.09e-05	0.000241	CcSEcCtD
Treprostinil—Asthenia—Capecitabine—breast cancer	9.08e-05	0.000241	CcSEcCtD
Treprostinil—Malaise—Doxorubicin—breast cancer	9.02e-05	0.000239	CcSEcCtD
Treprostinil—Anorexia—Methotrexate—breast cancer	8.98e-05	0.000238	CcSEcCtD
Treprostinil—Syncope—Doxorubicin—breast cancer	8.97e-05	0.000238	CcSEcCtD
Treprostinil—Pruritus—Capecitabine—breast cancer	8.96e-05	0.000238	CcSEcCtD
Treprostinil—Diarrhoea—Docetaxel—breast cancer	8.95e-05	0.000237	CcSEcCtD
Treprostinil—Palpitations—Doxorubicin—breast cancer	8.84e-05	0.000234	CcSEcCtD
Treprostinil—Oedema—Epirubicin—breast cancer	8.82e-05	0.000234	CcSEcCtD
Treprostinil—Hypotension—Methotrexate—breast cancer	8.81e-05	0.000234	CcSEcCtD
Treprostinil—Loss of consciousness—Doxorubicin—breast cancer	8.79e-05	0.000233	CcSEcCtD
Treprostinil—Infection—Epirubicin—breast cancer	8.76e-05	0.000233	CcSEcCtD
Treprostinil—Cough—Doxorubicin—breast cancer	8.73e-05	0.000232	CcSEcCtD
Treprostinil—Shock—Epirubicin—breast cancer	8.68e-05	0.00023	CcSEcCtD
Treprostinil—Diarrhoea—Capecitabine—breast cancer	8.66e-05	0.00023	CcSEcCtD
Treprostinil—Dizziness—Docetaxel—breast cancer	8.65e-05	0.000229	CcSEcCtD
Treprostinil—Thrombocytopenia—Epirubicin—breast cancer	8.64e-05	0.000229	CcSEcCtD
Treprostinil—Tachycardia—Epirubicin—breast cancer	8.61e-05	0.000228	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Methotrexate—breast cancer	8.59e-05	0.000228	CcSEcCtD
Treprostinil—Insomnia—Methotrexate—breast cancer	8.52e-05	0.000226	CcSEcCtD
Treprostinil—Chest pain—Doxorubicin—breast cancer	8.51e-05	0.000226	CcSEcCtD
Treprostinil—Arthralgia—Doxorubicin—breast cancer	8.51e-05	0.000226	CcSEcCtD
Treprostinil—Myalgia—Doxorubicin—breast cancer	8.51e-05	0.000226	CcSEcCtD
Treprostinil—Anxiety—Doxorubicin—breast cancer	8.48e-05	0.000225	CcSEcCtD
Treprostinil—Paraesthesia—Methotrexate—breast cancer	8.46e-05	0.000225	CcSEcCtD
Treprostinil—Discomfort—Doxorubicin—breast cancer	8.41e-05	0.000223	CcSEcCtD
Treprostinil—Anorexia—Epirubicin—breast cancer	8.41e-05	0.000223	CcSEcCtD
Treprostinil—Dyspnoea—Methotrexate—breast cancer	8.4e-05	0.000223	CcSEcCtD
Treprostinil—Dizziness—Capecitabine—breast cancer	8.37e-05	0.000222	CcSEcCtD
Treprostinil—Vomiting—Docetaxel—breast cancer	8.31e-05	0.000221	CcSEcCtD
Treprostinil—Dyspepsia—Methotrexate—breast cancer	8.3e-05	0.00022	CcSEcCtD
Treprostinil—Rash—Docetaxel—breast cancer	8.25e-05	0.000219	CcSEcCtD
Treprostinil—Hypotension—Epirubicin—breast cancer	8.24e-05	0.000219	CcSEcCtD
Treprostinil—Dermatitis—Docetaxel—breast cancer	8.24e-05	0.000219	CcSEcCtD
Treprostinil—Decreased appetite—Methotrexate—breast cancer	8.19e-05	0.000217	CcSEcCtD
Treprostinil—Headache—Docetaxel—breast cancer	8.19e-05	0.000217	CcSEcCtD
Treprostinil—Oedema—Doxorubicin—breast cancer	8.16e-05	0.000217	CcSEcCtD
Treprostinil—Fatigue—Methotrexate—breast cancer	8.13e-05	0.000216	CcSEcCtD
Treprostinil—Infection—Doxorubicin—breast cancer	8.11e-05	0.000215	CcSEcCtD
Treprostinil—Pain—Methotrexate—breast cancer	8.06e-05	0.000214	CcSEcCtD
Treprostinil—Vomiting—Capecitabine—breast cancer	8.05e-05	0.000214	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Epirubicin—breast cancer	8.04e-05	0.000213	CcSEcCtD
Treprostinil—Shock—Doxorubicin—breast cancer	8.03e-05	0.000213	CcSEcCtD
Treprostinil—Thrombocytopenia—Doxorubicin—breast cancer	7.99e-05	0.000212	CcSEcCtD
Treprostinil—Rash—Capecitabine—breast cancer	7.98e-05	0.000212	CcSEcCtD
Treprostinil—Insomnia—Epirubicin—breast cancer	7.98e-05	0.000212	CcSEcCtD
Treprostinil—Dermatitis—Capecitabine—breast cancer	7.98e-05	0.000212	CcSEcCtD
Treprostinil—Tachycardia—Doxorubicin—breast cancer	7.97e-05	0.000211	CcSEcCtD
Treprostinil—Headache—Capecitabine—breast cancer	7.93e-05	0.00021	CcSEcCtD
Treprostinil—Paraesthesia—Epirubicin—breast cancer	7.92e-05	0.00021	CcSEcCtD
Treprostinil—Dyspnoea—Epirubicin—breast cancer	7.86e-05	0.000209	CcSEcCtD
Treprostinil—Anorexia—Doxorubicin—breast cancer	7.78e-05	0.000206	CcSEcCtD
Treprostinil—Nausea—Docetaxel—breast cancer	7.77e-05	0.000206	CcSEcCtD
Treprostinil—Feeling abnormal—Methotrexate—breast cancer	7.77e-05	0.000206	CcSEcCtD
Treprostinil—Dyspepsia—Epirubicin—breast cancer	7.76e-05	0.000206	CcSEcCtD
Treprostinil—Gastrointestinal pain—Methotrexate—breast cancer	7.71e-05	0.000204	CcSEcCtD
Treprostinil—Decreased appetite—Epirubicin—breast cancer	7.67e-05	0.000203	CcSEcCtD
Treprostinil—Hypotension—Doxorubicin—breast cancer	7.63e-05	0.000202	CcSEcCtD
Treprostinil—Fatigue—Epirubicin—breast cancer	7.6e-05	0.000202	CcSEcCtD
Treprostinil—Pain—Epirubicin—breast cancer	7.54e-05	0.0002	CcSEcCtD
Treprostinil—Nausea—Capecitabine—breast cancer	7.52e-05	0.0002	CcSEcCtD
Treprostinil—Body temperature increased—Methotrexate—breast cancer	7.45e-05	0.000198	CcSEcCtD
Treprostinil—Abdominal pain—Methotrexate—breast cancer	7.45e-05	0.000198	CcSEcCtD
Treprostinil—Musculoskeletal discomfort—Doxorubicin—breast cancer	7.44e-05	0.000197	CcSEcCtD
Treprostinil—Insomnia—Doxorubicin—breast cancer	7.38e-05	0.000196	CcSEcCtD
Treprostinil—Paraesthesia—Doxorubicin—breast cancer	7.33e-05	0.000194	CcSEcCtD
Treprostinil—Dyspnoea—Doxorubicin—breast cancer	7.28e-05	0.000193	CcSEcCtD
Treprostinil—Feeling abnormal—Epirubicin—breast cancer	7.27e-05	0.000193	CcSEcCtD
Treprostinil—Gastrointestinal pain—Epirubicin—breast cancer	7.21e-05	0.000191	CcSEcCtD
Treprostinil—Dyspepsia—Doxorubicin—breast cancer	7.18e-05	0.000191	CcSEcCtD
Treprostinil—Decreased appetite—Doxorubicin—breast cancer	7.09e-05	0.000188	CcSEcCtD
Treprostinil—Fatigue—Doxorubicin—breast cancer	7.04e-05	0.000187	CcSEcCtD
Treprostinil—Pain—Doxorubicin—breast cancer	6.98e-05	0.000185	CcSEcCtD
Treprostinil—Body temperature increased—Epirubicin—breast cancer	6.97e-05	0.000185	CcSEcCtD
Treprostinil—Abdominal pain—Epirubicin—breast cancer	6.97e-05	0.000185	CcSEcCtD
Treprostinil—Asthenia—Methotrexate—breast cancer	6.76e-05	0.000179	CcSEcCtD
Treprostinil—Feeling abnormal—Doxorubicin—breast cancer	6.73e-05	0.000178	CcSEcCtD
Treprostinil—Gastrointestinal pain—Doxorubicin—breast cancer	6.67e-05	0.000177	CcSEcCtD
Treprostinil—Pruritus—Methotrexate—breast cancer	6.67e-05	0.000177	CcSEcCtD
Treprostinil—Abdominal pain—Doxorubicin—breast cancer	6.45e-05	0.000171	CcSEcCtD
Treprostinil—Body temperature increased—Doxorubicin—breast cancer	6.45e-05	0.000171	CcSEcCtD
Treprostinil—Diarrhoea—Methotrexate—breast cancer	6.45e-05	0.000171	CcSEcCtD
Treprostinil—Asthenia—Epirubicin—breast cancer	6.33e-05	0.000168	CcSEcCtD
Treprostinil—Pruritus—Epirubicin—breast cancer	6.24e-05	0.000166	CcSEcCtD
Treprostinil—Dizziness—Methotrexate—breast cancer	6.23e-05	0.000165	CcSEcCtD
Treprostinil—Diarrhoea—Epirubicin—breast cancer	6.04e-05	0.00016	CcSEcCtD
Treprostinil—Vomiting—Methotrexate—breast cancer	5.99e-05	0.000159	CcSEcCtD
Treprostinil—Rash—Methotrexate—breast cancer	5.94e-05	0.000158	CcSEcCtD
Treprostinil—Dermatitis—Methotrexate—breast cancer	5.94e-05	0.000158	CcSEcCtD
Treprostinil—Headache—Methotrexate—breast cancer	5.9e-05	0.000157	CcSEcCtD
Treprostinil—Asthenia—Doxorubicin—breast cancer	5.86e-05	0.000155	CcSEcCtD
Treprostinil—Dizziness—Epirubicin—breast cancer	5.83e-05	0.000155	CcSEcCtD
Treprostinil—Pruritus—Doxorubicin—breast cancer	5.77e-05	0.000153	CcSEcCtD
Treprostinil—Vomiting—Epirubicin—breast cancer	5.61e-05	0.000149	CcSEcCtD
Treprostinil—Nausea—Methotrexate—breast cancer	5.6e-05	0.000149	CcSEcCtD
Treprostinil—Diarrhoea—Doxorubicin—breast cancer	5.58e-05	0.000148	CcSEcCtD
Treprostinil—Rash—Epirubicin—breast cancer	5.56e-05	0.000148	CcSEcCtD
Treprostinil—Dermatitis—Epirubicin—breast cancer	5.56e-05	0.000147	CcSEcCtD
Treprostinil—Headache—Epirubicin—breast cancer	5.53e-05	0.000147	CcSEcCtD
Treprostinil—Dizziness—Doxorubicin—breast cancer	5.4e-05	0.000143	CcSEcCtD
Treprostinil—Nausea—Epirubicin—breast cancer	5.24e-05	0.000139	CcSEcCtD
Treprostinil—Vomiting—Doxorubicin—breast cancer	5.19e-05	0.000138	CcSEcCtD
Treprostinil—Rash—Doxorubicin—breast cancer	5.15e-05	0.000137	CcSEcCtD
Treprostinil—Dermatitis—Doxorubicin—breast cancer	5.14e-05	0.000136	CcSEcCtD
Treprostinil—Headache—Doxorubicin—breast cancer	5.11e-05	0.000136	CcSEcCtD
Treprostinil—Nausea—Doxorubicin—breast cancer	4.85e-05	0.000129	CcSEcCtD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CPT1A—breast cancer	2.89e-05	0.00011	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—COX11—breast cancer	2.88e-05	0.00011	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CG—breast cancer	2.88e-05	0.00011	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—H2AFX—breast cancer	2.88e-05	0.00011	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—IL2—breast cancer	2.88e-05	0.00011	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—E2F1—breast cancer	2.86e-05	0.000109	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PIK3CB—breast cancer	2.84e-05	0.000109	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—IL2—breast cancer	2.84e-05	0.000108	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—breast cancer	2.83e-05	0.000108	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TERT—breast cancer	2.83e-05	0.000108	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—HRAS—breast cancer	2.8e-05	0.000107	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—breast cancer	2.75e-05	0.000105	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FGFR1—breast cancer	2.75e-05	0.000105	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SPP1—breast cancer	2.75e-05	0.000105	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—CXCL8—breast cancer	2.73e-05	0.000104	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ERBB3—breast cancer	2.72e-05	0.000104	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FGFR2—breast cancer	2.71e-05	0.000104	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HIF1A—breast cancer	2.7e-05	0.000103	CbGpPWpGaD
Treprostinil—P2RY12—Hemostasis—AKT1—breast cancer	2.68e-05	0.000102	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—LEP—breast cancer	2.64e-05	0.000101	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CDA—breast cancer	2.64e-05	0.000101	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SHMT1—breast cancer	2.64e-05	0.000101	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CAV1—breast cancer	2.62e-05	9.99e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—IL2—breast cancer	2.61e-05	9.98e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TERT—breast cancer	2.6e-05	9.94e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP17A1—breast cancer	2.6e-05	9.94e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KDR—breast cancer	2.59e-05	9.88e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—breast cancer	2.58e-05	9.84e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLCO1B1—breast cancer	2.54e-05	9.69e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC2A5—breast cancer	2.54e-05	9.69e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CD—breast cancer	2.53e-05	9.67e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FGFR1—breast cancer	2.53e-05	9.65e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ESR1—breast cancer	2.52e-05	9.63e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—ALB—breast cancer	2.5e-05	9.54e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—FN1—breast cancer	2.49e-05	9.51e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HIF1A—breast cancer	2.49e-05	9.51e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOA2—breast cancer	2.48e-05	9.47e-05	CbGpPWpGaD
Treprostinil—PTGIR—Hemostasis—AKT1—breast cancer	2.47e-05	9.43e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NFKBIA—breast cancer	2.46e-05	9.4e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—APRT—breast cancer	2.45e-05	9.36e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NOTCH1—breast cancer	2.44e-05	9.3e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—LEP—breast cancer	2.43e-05	9.28e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CAV1—breast cancer	2.41e-05	9.19e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—FASN—breast cancer	2.4e-05	9.18e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—breast cancer	2.39e-05	9.14e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—NOS3—breast cancer	2.39e-05	9.13e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—APC—breast cancer	2.38e-05	9.1e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KIT—breast cancer	2.38e-05	9.1e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CG—breast cancer	2.38e-05	9.1e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KDR—breast cancer	2.38e-05	9.09e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EGF—breast cancer	2.36e-05	8.99e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ESR1—breast cancer	2.32e-05	8.86e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ESRRA—breast cancer	2.3e-05	8.8e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ANGPTL4—breast cancer	2.3e-05	8.8e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—FN1—breast cancer	2.29e-05	8.75e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—MAPK3—breast cancer	2.28e-05	8.71e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NFKBIA—breast cancer	2.26e-05	8.65e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NOTCH1—breast cancer	2.24e-05	8.56e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—BRAF—breast cancer	2.24e-05	8.55e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CB—breast cancer	2.21e-05	8.43e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CG—breast cancer	2.19e-05	8.37e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KIT—breast cancer	2.19e-05	8.37e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—APC—breast cancer	2.19e-05	8.37e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—breast cancer	2.19e-05	8.36e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTGS2—breast cancer	2.19e-05	8.35e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GPI—breast cancer	2.18e-05	8.34e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HADHB—breast cancer	2.18e-05	8.34e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IGF1—breast cancer	2.18e-05	8.33e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKT2—breast cancer	2.18e-05	8.33e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—EGFR—breast cancer	2.17e-05	8.29e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EGF—breast cancer	2.17e-05	8.28e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—MAPK3—breast cancer	2.1e-05	8.02e-05	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—MAPK3—breast cancer	2.1e-05	8e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CD—breast cancer	2.09e-05	8e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOA1—breast cancer	2.09e-05	7.98e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ALDH1A1—breast cancer	2.08e-05	7.95e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ALDH7A1—breast cancer	2.08e-05	7.95e-05	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—PIK3CA—breast cancer	2.08e-05	7.92e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SERPINE1—breast cancer	2.07e-05	7.91e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—BRAF—breast cancer	2.06e-05	7.87e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—breast cancer	2.06e-05	7.86e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—KRAS—breast cancer	2.05e-05	7.83e-05	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—MYC—breast cancer	2.04e-05	7.78e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IGF1—breast cancer	2.01e-05	7.67e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKT2—breast cancer	2.01e-05	7.66e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—EGFR—breast cancer	2e-05	7.63e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NME1—breast cancer	2e-05	7.63e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PHGDH—breast cancer	2e-05	7.63e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—UMPS—breast cancer	2e-05	7.63e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ADSL—breast cancer	2e-05	7.63e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—FHL2—breast cancer	2e-05	7.63e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—NOS3—breast cancer	1.98e-05	7.55e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—BRIP1—breast cancer	1.96e-05	7.48e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—LDHB—breast cancer	1.96e-05	7.48e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HPSE—breast cancer	1.96e-05	7.48e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CD—breast cancer	1.93e-05	7.36e-05	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—PIK3CA—breast cancer	1.91e-05	7.29e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SERPINE1—breast cancer	1.91e-05	7.28e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PTEN—breast cancer	1.91e-05	7.28e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—KRAS—breast cancer	1.89e-05	7.21e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—PIK3CA—breast cancer	1.88e-05	7.19e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MDM2—breast cancer	1.88e-05	7.17e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—RAF1—breast cancer	1.87e-05	7.14e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—RELA—breast cancer	1.86e-05	7.11e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HMMR—breast cancer	1.86e-05	7.09e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ABCC1—breast cancer	1.86e-05	7.09e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA3—breast cancer	1.86e-05	7.09e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—ERBB2—breast cancer	1.85e-05	7.07e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MTOR—breast cancer	1.83e-05	6.97e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CB—breast cancer	1.83e-05	6.97e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—NOS3—breast cancer	1.82e-05	6.95e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PPARGC1B—breast cancer	1.8e-05	6.87e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CXCL8—breast cancer	1.75e-05	6.7e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—breast cancer	1.75e-05	6.69e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—breast cancer	1.75e-05	6.69e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—HRAS—breast cancer	1.74e-05	6.66e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—PIK3CA—breast cancer	1.73e-05	6.62e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MDM2—breast cancer	1.73e-05	6.59e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—RAF1—breast cancer	1.72e-05	6.57e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—RELA—breast cancer	1.71e-05	6.54e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN1B—breast cancer	1.71e-05	6.54e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—ERBB2—breast cancer	1.7e-05	6.5e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CA9—breast cancer	1.7e-05	6.48e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA4—breast cancer	1.7e-05	6.48e-05	CbGpPWpGaD
Treprostinil—P2RY12—GPCR downstream signaling—AKT1—breast cancer	1.7e-05	6.47e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MTOR—breast cancer	1.68e-05	6.42e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CB—breast cancer	1.68e-05	6.42e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CASP3—breast cancer	1.68e-05	6.41e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IL2—breast cancer	1.68e-05	6.4e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—breast cancer	1.68e-05	6.4e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—IL6—breast cancer	1.67e-05	6.37e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—breast cancer	1.66e-05	6.34e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA2—breast cancer	1.66e-05	6.32e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GPX2—breast cancer	1.66e-05	6.32e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SULT1A1—breast cancer	1.63e-05	6.24e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GPX4—breast cancer	1.63e-05	6.24e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CCND1—breast cancer	1.63e-05	6.24e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—JUN—breast cancer	1.63e-05	6.23e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CTNNB1—breast cancer	1.62e-05	6.18e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CXCL8—breast cancer	1.61e-05	6.17e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—HRAS—breast cancer	1.6e-05	6.13e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—IDH1—breast cancer	1.6e-05	6.1e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTA1—breast cancer	1.6e-05	6.1e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MMP9—breast cancer	1.59e-05	6.06e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—CDKN1A—breast cancer	1.58e-05	6.04e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NAT2—breast cancer	1.58e-05	6.03e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PTEN—breast cancer	1.58e-05	6.02e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN1B—breast cancer	1.58e-05	6.02e-05	CbGpPWpGaD
Treprostinil—PTGIR—GPCR downstream signaling—AKT1—breast cancer	1.56e-05	5.96e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CASP3—breast cancer	1.55e-05	5.9e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MAPK8—breast cancer	1.54e-05	5.89e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IL2—breast cancer	1.54e-05	5.89e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling by GPCR—AKT1—breast cancer	1.54e-05	5.88e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—IL6—breast cancer	1.54e-05	5.86e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CCND1—breast cancer	1.5e-05	5.74e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—JUN—breast cancer	1.5e-05	5.73e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CTNNB1—breast cancer	1.49e-05	5.69e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—SRC—breast cancer	1.46e-05	5.59e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MMP9—breast cancer	1.46e-05	5.58e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—CDKN1A—breast cancer	1.46e-05	5.56e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PTEN—breast cancer	1.45e-05	5.54e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—breast cancer	1.43e-05	5.45e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—VEGFA—breast cancer	1.43e-05	5.44e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MAPK8—breast cancer	1.42e-05	5.42e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling by GPCR—AKT1—breast cancer	1.42e-05	5.41e-05	CbGpPWpGaD
Treprostinil—PPARD—Gene Expression—AKT1—breast cancer	1.41e-05	5.4e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—STAT3—breast cancer	1.41e-05	5.39e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MED12—breast cancer	1.38e-05	5.29e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—DPYD—breast cancer	1.38e-05	5.29e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ALDOA—breast cancer	1.36e-05	5.2e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MAPK3—breast cancer	1.35e-05	5.15e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—SRC—breast cancer	1.35e-05	5.14e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—PIK3CA—breast cancer	1.35e-05	5.14e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOA3—breast cancer	1.32e-05	5.05e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC2A2—breast cancer	1.31e-05	5.02e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—VEGFA—breast cancer	1.31e-05	5.01e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—MYC—breast cancer	1.31e-05	5.01e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TGFB1—breast cancer	1.31e-05	4.99e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	1.3e-05	4.96e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—STAT3—breast cancer	1.3e-05	4.96e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CPT1A—breast cancer	1.29e-05	4.91e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MTR—breast cancer	1.29e-05	4.91e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ABCG2—breast cancer	1.29e-05	4.91e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—EGFR—breast cancer	1.28e-05	4.9e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HPGDS—breast cancer	1.26e-05	4.82e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HBA1—breast cancer	1.25e-05	4.79e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MAPK3—breast cancer	1.24e-05	4.74e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTT1—breast cancer	1.22e-05	4.67e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ACHE—breast cancer	1.22e-05	4.67e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—KRAS—breast cancer	1.21e-05	4.63e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—MYC—breast cancer	1.21e-05	4.61e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TGFB1—breast cancer	1.2e-05	4.6e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—EGFR—breast cancer	1.18e-05	4.51e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP17A1—breast cancer	1.16e-05	4.42e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ENO1—breast cancer	1.15e-05	4.38e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS1—breast cancer	1.15e-05	4.38e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	1.14e-05	4.36e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	1.13e-05	4.31e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP2D6—breast cancer	1.13e-05	4.3e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—KRAS—breast cancer	1.12e-05	4.26e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—PIK3CA—breast cancer	1.11e-05	4.25e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOA2—breast cancer	1.1e-05	4.22e-05	CbGpPWpGaD
Treprostinil—PPARD—Metabolism—AKT1—breast cancer	1.1e-05	4.2e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—TP53—breast cancer	1.08e-05	4.11e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—FASN—breast cancer	1.07e-05	4.09e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—BCHE—breast cancer	1.07e-05	4.07e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC5A5—breast cancer	1.05e-05	4.02e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—HRAS—breast cancer	1.03e-05	3.93e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—PIK3CA—breast cancer	1.02e-05	3.91e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NQO1—breast cancer	1.02e-05	3.88e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—SLC2A1—breast cancer	1.02e-05	3.88e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	9.96e-06	3.8e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP3A4—breast cancer	9.92e-06	3.79e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—TP53—breast cancer	9.91e-06	3.78e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	9.87e-06	3.77e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—IL6—breast cancer	9.86e-06	3.76e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP1B1—breast cancer	9.75e-06	3.72e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HSP90AA1—breast cancer	9.57e-06	3.65e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—HRAS—breast cancer	9.48e-06	3.62e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOA1—breast cancer	9.31e-06	3.55e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—STK11—breast cancer	9.17e-06	3.5e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP19A1—breast cancer	9.17e-06	3.5e-05	CbGpPWpGaD
Treprostinil—P2RY12—Signaling Pathways—AKT1—breast cancer	9.09e-06	3.47e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—IL6—breast cancer	9.07e-06	3.46e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	8.61e-06	3.29e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—COMT—breast cancer	8.53e-06	3.26e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTP1—breast cancer	8.49e-06	3.24e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—HMOX1—breast cancer	8.37e-06	3.2e-05	CbGpPWpGaD
Treprostinil—PTGIR—Signaling Pathways—AKT1—breast cancer	8.37e-06	3.2e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ITPR1—breast cancer	8.35e-06	3.19e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ABCB1—breast cancer	8.03e-06	3.07e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—TYMS—breast cancer	7.89e-06	3.01e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NCOR1—breast cancer	7.8e-06	2.98e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GSTM1—breast cancer	7.8e-06	2.98e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PLA2G4A—breast cancer	7.8e-06	2.98e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—GPX1—breast cancer	7.47e-06	2.85e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CYP1A1—breast cancer	7.39e-06	2.82e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ERCC2—breast cancer	7.33e-06	2.8e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—MTHFR—breast cancer	6.89e-06	2.63e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—CAV1—breast cancer	6.36e-06	2.43e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	6.07e-06	2.32e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CG—breast cancer	5.79e-06	2.21e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CD—breast cancer	5.09e-06	1.94e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—ALB—breast cancer	5.03e-06	1.92e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—NOS3—breast cancer	4.81e-06	1.84e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CB—breast cancer	4.44e-06	1.69e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTGS2—breast cancer	4.4e-06	1.68e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PTEN—breast cancer	3.83e-06	1.46e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—PIK3CA—breast cancer	2.7e-06	1.03e-05	CbGpPWpGaD
Treprostinil—CYP2C9—Metabolism—AKT1—breast cancer	2.21e-06	8.44e-06	CbGpPWpGaD
